Evidence map›Paper›PMID 39512528›Full record

ArticleContemporary oncology (Poznan, Poland)2024

P-selectin glycoprotein ligand-1 is diversely expressed in the primary tumour and venous thrombus of clear cell renal cancer and correlates with poor overall survival.

Rafał Pęksa, Sumit Sharma, Michał Kunc, Marta Popęda, Le Qu, Mikołaj Frankiewicz, Marcin Folwarski, Piotr Radziszewski, Łukasz Zapała

Abstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rafał Pęksa *Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Sumit Sharma *Clinic of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Michał KuncDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Marta PopędaDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Le QuDepartment of Urology Jinling Hospital Affiliated Hospital of Medical School Nanjing University, Nanjing Jiangsu, China.
Mikołaj FrankiewiczDepartment of Urology, Medical University of Gdańsk, Gdańsk, Poland.
Marcin FolwarskiDepartment of Clinical Nutrition and Dietetics, Medical University of Gdańsk, Gdańsk, Poland.
Piotr RadziszewskiClinic of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Łukasz ZapałaClinic of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In clear cell renal cell carcinoma (ccRCC), intravascular extension often results in neoplastic thrombus formation, impacting patient outcomes. Material and methods: We assessed P-selectin glycoprotein ligand-1 (PSGL-1) expression in the primary tumours and thrombi of 82 ccRCC patients. Results: Notably, PSGL-1 expression varied between tumour compartments, with higher prevalence in thrombus tumour cells (TC) and primary tumour-associated immune cells (TAIC). Positive TC PSGL-1 correlated with high-grade histology, while TAIC PSGL-1 was associated with tumour necrosis. Univariate survival analysis identified PSGL-1 positivity in TC of primary tumours and TAIC in thrombi as indicators of poorer overall survival. These findings suggest a potential role for PSGL-1 in the mediation of tumour thrombus formation, highlighting its relevance in biology of ccRCC. Conclusions: The increased expression of PSGL-1 in venous thrombi suggests its potential role in facilitating TC interactions with platelets and endothelium, potentially contributing to metastatic spread and worse outcomes. Understanding these expression patterns may aid in the development of novel therapeutic strategies and personalised treatment approaches for ccRCC patients.

Indexed as

biomarkerP-selectin glycoprotein ligand-1renal cell cancertumour thrombus

Identifiers

PMID39512528
PMCPMC11538979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.